As of 7 April 2020, Zentiva Group a.s. has acquired Alvogen’s Central and Eastern European (CEE) business. The acquisition brings together two leading branded generic and OTC businesses in the CEE region. ZENTIVA is headquartered in Prague and reaches over 40 million patients in 25 European countries. The growth of our organization and the combination of both leading business bring great opportunities: